Genomic Valley Bio.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Genomic Valley Biotech Ltd GENI.BO:
GENOMIC VALLEY BIOTECH- PROMOTER SOLD 2.25% STAKE IN CO VIA OPEN MARKET
Source text for Eikon: ID:nBSE6YLXyv
Further company coverage: GENI.BO
Genomic Valley Biotech Ltd GENI.BO:
GENOMIC VALLEY BIOTECH- PROMOTER SOLD 2.25% STAKE IN CO VIA OPEN MARKET
Source text for Eikon: ID:nBSE6YLXyv
Further company coverage: GENI.BO
June 30 (Reuters) - Genomic Valley Biotech Ltd GENI.BO:
NAMES YOGESH AGRAWAL AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE7BTY7H
Further company coverage: GENI.BO
(([email protected];))
June 30 (Reuters) - Genomic Valley Biotech Ltd GENI.BO:
NAMES YOGESH AGRAWAL AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE7BTY7H
Further company coverage: GENI.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Genomic Valley Bio. do?
Established in 1994, Genomic Valley Biotech Ltd is a company focused on sales & services in the horticulture sector.
Who are the competitors of Genomic Valley Bio.?
Genomic Valley Bio. major competitors are Omega Ag-SeedsPunjab, Shri Mahalaxmi Agri, Tarai Foods, Camson Bio, Thakkers Group, Jayatma Spinners, Asian Warehousing. Market Cap of Genomic Valley Bio. is ₹9 Crs. While the median market cap of its peers are ₹8 Crs.
Is Genomic Valley Bio. financially stable compared to its competitors?
Genomic Valley Bio. seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Genomic Valley Bio. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Genomic Valley Bio. latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Genomic Valley Bio. allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Genomic Valley Bio. balance sheet?
Balance sheet of Genomic Valley Bio. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Genomic Valley Bio. improving?
The profit is oscillating. The profit of Genomic Valley Bio. is ₹0.36 Crs for Mar 2025, ₹0.02 Crs for Mar 2024 and ₹0.65 Crs for Mar 2023
Is the debt of Genomic Valley Bio. increasing or decreasing?
Yes, The net debt of Genomic Valley Bio. is increasing. Latest net debt of Genomic Valley Bio. is -₹0.03 Crs as of Mar-26. This is greater than Mar-25 when it was -₹0.07 Crs.
Is Genomic Valley Bio. stock expensive?
Yes, Genomic Valley Bio. is expensive. Latest PE of Genomic Valley Bio. is 290, while 3 year average PE is 106. Also latest EV/EBITDA of Genomic Valley Bio. is 195 while 3yr average is 98.34.
Has the share price of Genomic Valley Bio. grown faster than its competition?
Genomic Valley Bio. has given lower returns compared to its competitors. Genomic Valley Bio. has grown at ~-18.58% over the last 2yrs while peers have grown at a median rate of 0.0%
Is the promoter bullish about Genomic Valley Bio.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Genomic Valley Bio. is 46.06% and last quarter promoter holding is 46.06%.
Are mutual funds buying/selling Genomic Valley Bio.?
There is Insufficient data to gauge this.